The interface between pharmacoepidemiology and pharmacogenetics
- 27 December 2000
- journal article
- review article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 410 (2-3), 121-130
- https://doi.org/10.1016/s0014-2999(00)00810-4
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- G-protein β3 subunit 825T allele and response to dietary salt in normotensive menJournal of Hypertension, 2000
- Pharmacogenomics: The promise of personalized medicineAAPS PharmSci, 2000
- Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?Clinical Genetics, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- How will knowledge of the human genome affect drug therapy?British Journal of Clinical Pharmacology, 1999
- Genetic Variation as a Guide to Drug DevelopmentScience, 1998
- PharmacogenomicsCurrent Opinion in Nephrology and Hypertension, 1998
- The Effect of Vitamin D Supplementation on the Bone Mineral Density of the Femoral Neck Is Associated with Vitamin D Receptor GenotypeJournal of Bone and Mineral Research, 1997
- Influence of the Angiotensin II Type 1 Receptor Gene Polymorphism on the Effects of Perindopril and Nitrendipine on Arterial Stiffness in Hypertensive IndividualsHypertension, 1996
- Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genesJournal of Hypertension, 1996